Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Next Previous
Trial Profile

An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 011 (Primary) ; Capecitabine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors CARsgen

Most Recent Events

  • 23 May 2024 Status changed from active, no longer recruiting to completed.
  • 21 Jan 2023 Results of preliminary data on AB011 both as monotherapy and combined with CAPOX in patients with advanced solid tumors presented at the 2023 Gastrointestinal Cancers Symposium
  • 04 Jan 2023 Planned primary completion date changed from 3 Dec 2022 to 27 Jul 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top